METHOD OF CREATING A LIVE VACCINE AGAINST COVID-19 BASED ON THE PROBIOTIC STRAIN ENTEROCOCCUS FAECIUM L3 AND A LIVE VACCINE ENTEROCOCCUS FAECIUM L3-PENTF-COVID-19 Russian patent published in 2021 - IPC C12N1/00 A61K39/215 A61P31/14 C12N15/00 

FIELD: medicine; virology; microbiology; molecular genetics; biotechnology.

SUBSTANCE: invention relates to medicine, virology, microbiology, molecular genetics and biotechnology. Presented is a live vaccine Enterococcus faecium L3-pentF-covid-19, containing a clone of enterococci COVID 19+ with a DNA region SEQ ID No: 1 introduced into its genome, providing expression of a protein having the amino acid sequence SEQID No: 2, stimulating humoral and cellular immunity in against the SARS-CoV-2 virus. Also presented is a method of obtaining the specified vaccine based on the probiotic strain Enterococcus faecium L3, modified as a result of electroporation of the culture of enterococci Enterococcus faecium L3 of the recombinant plasmid DNA pentF-covid-19, SEQ ID No: 1, characterized by the fact that the the pspf region of the plasmid pentF-pspf is replaced by a fragment of the gene of the SARS-CoV-2 spike protein, while the pentF-covid-19 DNA encodes the amino acid sequence SEQ ID No: 2, which functions as the spike protein of the SARS-CoV-2 virus, capable of stimulating humoral and cellular immunity against SARS-CoV-2 virus.

EFFECT: oral administration of the Enterococcus faecium pentF-covid-19 vaccine stimulates the development of a specific systemic and local immune response, which is manifested by the production of specific immunoglobulins of classes G and A, as well as increased production of interferon gamma in vaccinated animals.

2 cl, 7 dwg, 1 tbl, 5 ex